{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T13:18:21Z","timestamp":1788959901567,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"DOI":"10.1007\/s10557-026-07904-4","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T12:31:24Z","timestamp":1782909084000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Association of In-Hospital Dapagliflozin Initiation with Favorable left Ventricular Remodeling in Patients with Acute Myocardial Infarction and Heart Failure: A Retrospective Cohort Study"],"prefix":"10.1007","author":[{"given":"Yongzheng","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengqi","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingyuan","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongli","family":"Qiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8914-6713","authenticated-orcid":false,"given":"Xinwei","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"issue":"3","key":"7904_CR1","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jchf.2017.09.015","volume":"6","author":"MC Bahit","year":"2018","unstructured":"Bahit MC, Kochar A, Granger CB. Post-Myocardial Infarction Heart Failure. JACC Heart Fail. 2018;6(3):179\u201386. https:\/\/doi.org\/10.1016\/j.jchf.2017.09.015.","journal-title":"JACC Heart Fail"},{"issue":"4","key":"7904_CR2","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.recesp.2011.10.027","volume":"65","author":"Y Juilli\u00e8re","year":"2012","unstructured":"Juilli\u00e8re Y, Cambou JP, Bataille V, et al. Heart failure in acute myocardial infarction: a comparison between patients with or without heart failure criteria from the FAST-MI registry. Rev Esp Cardiol (Engl Ed). 2012;65(4):326\u201333. https:\/\/doi.org\/10.1016\/j.recesp.2011.10.027.","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"issue":"21","key":"7904_CR3","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303.","journal-title":"N Engl J Med"},{"issue":"15","key":"7904_CR4","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383(15):1413\u201324. https:\/\/doi.org\/10.1056\/NEJMoa2022190.","journal-title":"N Engl J Med"},{"issue":"36","key":"7904_CR5","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599\u2013726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368.","journal-title":"Eur Heart J"},{"issue":"1","key":"7904_CR6","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s12933-023-01814-7","volume":"22","author":"C Sardu","year":"2023","unstructured":"Sardu C, Trotta MC, Sasso FC, et al. SGLT2-inhibitors effects on the coronary fibrous cap thickness and MACEs in diabetic patients with inducible myocardial ischemia and multi vessels non-obstructive coronary artery stenosis. Cardiovasc Diabetol. 2023;22(1):80. https:\/\/doi.org\/10.1186\/s12933-023-01814-7.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"7904_CR7","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12933-023-02118-6","volume":"23","author":"R Marfella","year":"2024","unstructured":"Marfella R, Prattichizzo F, Sardu C, et al. GLP-1 receptor agonists-SGLT-2 inhibitors combination therapy and cardiovascular events after acute myocardial infarction: an observational study in patients with type 2 diabetes. Cardiovasc Diabetol. 2024;23(1):10. https:\/\/doi.org\/10.1186\/s12933-023-02118-6.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"7904_CR8","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12916-023-02781-2","volume":"21","author":"R Marfella","year":"2023","unstructured":"Marfella R, Sardu C, D\u2019Onofrio N, et al. SGLT-2 inhibitors and in-stent restenosis-related events after acute myocardial infarction: an observational study in patients with type 2 diabetes. BMC Med. 2023;21(1):71. https:\/\/doi.org\/10.1186\/s12916-023-02781-2.","journal-title":"BMC Med"},{"key":"7904_CR9","doi-asserted-by":"publisher","first-page":"107759","DOI":"10.1016\/j.phrs.2025.107759","volume":"216","author":"C Sardu","year":"2025","unstructured":"Sardu C, Trotta MC, Marfella LV, et al. Effects of SGLT2i therapy on cardiac electrophysiological properties and arrhythmias in diabetic patients with implantable cardiac defibrillator. Pharmacol Res. 2025;216:107759. https:\/\/doi.org\/10.1016\/j.phrs.2025.107759.","journal-title":"Pharmacol Res"},{"key":"7904_CR10","doi-asserted-by":"publisher","first-page":"112452","DOI":"10.1016\/j.diabres.2025.112452","volume":"228","author":"C Sardu","year":"2025","unstructured":"Sardu C, Marfella LV, Rinaldi L, et al. Effects of combination therapy with SGLT2 inhibitors and GLP-1 receptor agonists on CRT response and clinical outcomes in in type 2 diabetes mellitus patients receiving chronic anti-diabetic medications: A multicenter observational study. Diabetes Res Clin Pract. 2025;228:112452. https:\/\/doi.org\/10.1016\/j.diabres.2025.112452.","journal-title":"Diabetes Res Clin Pract"},{"key":"7904_CR11","doi-asserted-by":"publisher","first-page":"777083","DOI":"10.3389\/fphar.2021.777083","volume":"12","author":"C Sardu","year":"2021","unstructured":"Sardu C, Massetti M, Testa N, et al. Effects of Sodium-Glucose Transporter 2 Inhibitors (SGLT2-I) in Patients With Ischemic Heart Disease (IHD) Treated by Coronary Artery Bypass Grafting via MiECC: Inflammatory Burden, and Clinical Outcomes at 5 Years of Follow-Up. Front Pharmacol. 2021;12:777083. https:\/\/doi.org\/10.3389\/fphar.2021.777083.","journal-title":"Front Pharmacol"},{"issue":"4","key":"7904_CR12","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.jacc.2019.11.031","volume":"75","author":"TA Zelniker","year":"2020","unstructured":"Zelniker TA, Braunwald E. Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020;75(4):422\u201334. https:\/\/doi.org\/10.1016\/j.jacc.2019.11.031.","journal-title":"J Am Coll Cardiol"},{"issue":"10354","key":"7904_CR13","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","volume":"400","author":"M Vaduganathan","year":"2022","unstructured":"Vaduganathan M, Docherty KF, Claggett BL, et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet. 2022;400(10354):757\u201367. https:\/\/doi.org\/10.1016\/S0140-6736(22)01429-5.","journal-title":"Lancet"},{"issue":"8","key":"7904_CR14","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1002\/ejhf.2884","volume":"25","author":"DA Pascual-Figal","year":"2023","unstructured":"Pascual-Figal DA, Zamorano JL, Domingo M, et al. Impact of dapagliflozin on cardiac remodelling in patients with chronic heart failure: The DAPA-MODA study. Eur J Heart Fail. 2023;25(8):1352\u201360. https:\/\/doi.org\/10.1002\/ejhf.2884.","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"7904_CR15","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.jacc.2020.11.008","volume":"77","author":"CG Santos-Gallego","year":"2021","unstructured":"Santos-Gallego CG, Vargas-Delgado AP, Requena-Ibanez JA, et al. Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction. J Am Coll Cardiol. 2021;77(3):243\u201355. https:\/\/doi.org\/10.1016\/j.jacc.2020.11.008.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"7904_CR16","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ejphar.2003.12.016","volume":"486","author":"HY Sun","year":"2004","unstructured":"Sun HY, Wang NP, Halkos ME, et al. Involvement of Na+\/H+ exchanger in hypoxia\/re-oxygenation-induced neonatal rat cardiomyocyte apoptosis. Eur J Pharmacol. 2004;486(2):121\u201331. https:\/\/doi.org\/10.1016\/j.ejphar.2003.12.016.","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"7904_CR17","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1161\/01.hyp.0000051502.93374.1c","volume":"41","author":"HE Cingolani","year":"2003","unstructured":"Cingolani HE, Rebolledo OR, Portiansky EL, P\u00e9rez NG, Camili\u00f3n de Hurtado MC. Regression of hypertensive myocardial fibrosis by Na(+)\/H(+) exchange inhibition. Hypertension. 2003;41(2):373\u20137. https:\/\/doi.org\/10.1161\/01.hyp.0000051502.93374.1c.","journal-title":"Hypertension"},{"issue":"1","key":"7904_CR18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12933-019-0816-2","volume":"18","author":"C Li","year":"2019","unstructured":"Li C, Zhang J, Xue M, et al. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. Cardiovasc Diabetol. 2019;18(1):15. https:\/\/doi.org\/10.1186\/s12933-019-0816-2.","journal-title":"Cardiovasc Diabetol"},{"issue":"21","key":"7904_CR19","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1161\/CIRCULATIONAHA.124.069217","volume":"149","author":"AF Hernandez","year":"2024","unstructured":"Hernandez AF, Udell JA, Jones WS, et al. Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI Trial. Circulation. 2024;149(21):1627\u201338. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.124.069217.","journal-title":"Circulation"},{"issue":"16","key":"7904_CR20","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1056\/NEJMoa2314051","volume":"390","author":"J Butler","year":"2024","unstructured":"Butler J, Jones WS, Udell JA, et al. Empagliflozin after Acute Myocardial Infarction. N Engl J Med. 2024;390(16):1455\u201366. https:\/\/doi.org\/10.1056\/NEJMoa2314051.","journal-title":"N Engl J Med"},{"issue":"41","key":"7904_CR21","doi-asserted-by":"publisher","first-page":"4421","DOI":"10.1093\/eurheartj\/ehac494","volume":"43","author":"D von Lewinski","year":"2022","unstructured":"von Lewinski D, Kolesnik E, Tripolt NJ, et al. Empagliflozin in acute myocardial infarction: the EMMY trial. Eur Heart J. 2022;43(41):4421\u201332. https:\/\/doi.org\/10.1093\/eurheartj\/ehac494.","journal-title":"Eur Heart J"},{"issue":"5","key":"7904_CR22","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1007\/s12265-022-10220-5","volume":"15","author":"HM Salah","year":"2022","unstructured":"Salah HM, Verma S, Santos-Gallego CG, et al. Sodium-Glucose Cotransporter 2 Inhibitors and Cardiac Remodeling. J Cardiovasc Transl Res. 2022;15(5):944\u201356. https:\/\/doi.org\/10.1007\/s12265-022-10220-5.","journal-title":"J Cardiovasc Transl Res"},{"issue":"3","key":"7904_CR23","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Multivar Behav Res. 2011;46(3):399\u2013424. https:\/\/doi.org\/10.1080\/00273171.2011.568786.","journal-title":"Multivar Behav Res"},{"issue":"5","key":"7904_CR24","doi-asserted-by":"publisher","first-page":"154","DOI":"10.31083\/j.rcm2505154","volume":"25","author":"Z Li","year":"2024","unstructured":"Li Z, Li A, Sun D, Shu Y. Effect of SGLT-2 Inhibitors on Prognosis in Diabetic Patients with Acute Myocardial Infarction: A Systematic Review and Meta-Analysis. Rev Cardiovasc Med. 2024;25(5):154. https:\/\/doi.org\/10.31083\/j.rcm2505154.","journal-title":"Rev Cardiovasc Med"},{"issue":"12","key":"7904_CR25","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022;387(12):1089\u201398. https:\/\/doi.org\/10.1056\/NEJMoa2206286.","journal-title":"N Engl J Med"},{"issue":"14","key":"7904_CR26","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1093\/eurheartj\/ehm184","volume":"28","author":"P Sorajja","year":"2007","unstructured":"Sorajja P, Gersh BJ, Cox DA, et al. Impact of multivessel disease on reperfusion success and clinical outcomes in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. Eur Heart J. 2007;28(14):1709\u201316. https:\/\/doi.org\/10.1093\/eurheartj\/ehm184.","journal-title":"Eur Heart J"},{"issue":"10","key":"7904_CR27","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1161\/circresaha.121.318241","volume":"128","author":"GD Lopaschuk","year":"2021","unstructured":"Lopaschuk GD, Karwi QG, Tian R, Wende AR, Abel ED. Cardiac Energy Metabolism in Heart Failure. Circ Res. 2021;128(10):1487\u2013513. https:\/\/doi.org\/10.1161\/circresaha.121.318241.","journal-title":"Circ Res"},{"key":"7904_CR28","doi-asserted-by":"publisher","first-page":"107424842413011","DOI":"10.1177\/10742484241301191","volume":"29","author":"J Wan","year":"2024","unstructured":"Wan J, Xu F, Zuo H, et al. Impact of SGLT2 Inhibitors on Left Ventricular Remodeling in Diabetic Patients with Acute Myocardial Infarction. J Cardiovasc Pharmacol Ther. 2024;29:10742484241301191. https:\/\/doi.org\/10.1177\/10742484241301191.","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"3","key":"7904_CR29","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1002\/ejhf.3560","volume":"27","author":"J Carberry","year":"2025","unstructured":"Carberry J, Petrie MC, Lee MMY, et al. Empagliflozin to prevent worsening of left ventricular volumes and systolic function after myocardial infarction (EMPRESS-MI). Eur J Heart Fail. 2025;27(3):566\u201376. https:\/\/doi.org\/10.1002\/ejhf.3560.","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"7904_CR30","doi-asserted-by":"publisher","first-page":"508","DOI":"10.2337\/dci19-0074","volume":"43","author":"M Packer","year":"2020","unstructured":"Packer M. SGLT2 Inhibitors Produce Cardiorenal Benefits by Promoting Adaptive Cellular Reprogramming to Induce a State of Fasting Mimicry: A Paradigm Shift in Understanding Their Mechanism of Action. Diabetes Care. 2020;43(3):508\u201311. https:\/\/doi.org\/10.2337\/dci19-0074.","journal-title":"Diabetes Care"},{"key":"7904_CR31","doi-asserted-by":"publisher","first-page":"104268","DOI":"10.1016\/j.mvr.2021.104268","volume":"139","author":"Y Zhong","year":"2022","unstructured":"Zhong Y, Yu X, Li X, Zhou H, Wang Y. Augmented early aged neutrophil infiltration contributes to late remodeling post myocardial infarction. Microvasc Res. 2022;139:104268. https:\/\/doi.org\/10.1016\/j.mvr.2021.104268.","journal-title":"Microvasc Res"},{"issue":"36","key":"7904_CR32","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","volume":"45","author":"C Vrints","year":"2024","unstructured":"Vrints C, Andreotti F, Koskinas KC, et al. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024;45(36):3415\u2013537. https:\/\/doi.org\/10.1093\/eurheartj\/ehae177.","journal-title":"Eur Heart J"},{"issue":"18","key":"7904_CR33","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/cir.0000000000001063","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895\u20131032. https:\/\/doi.org\/10.1161\/cir.0000000000001063.","journal-title":"Circulation"},{"issue":"3","key":"7904_CR34","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","volume":"28","author":"AA Voors","year":"2022","unstructured":"Voors AA, Angermann CE, Teerlink JR, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022;28(3):568\u201374. https:\/\/doi.org\/10.1038\/s41591-021-01659-1.","journal-title":"Nat Med"},{"issue":"2","key":"7904_CR35","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2030183","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. N Engl J Med. 2021;384(2):117\u201328. https:\/\/doi.org\/10.1056\/NEJMoa2030183.","journal-title":"N Engl J Med"},{"issue":"2","key":"7904_CR36","doi-asserted-by":"publisher","first-page":"45741","DOI":"10.31083\/rcm45741","volume":"27","author":"MG Bellicini","year":"2026","unstructured":"Bellicini MG, Bradycardia, Hyperkalemia R. Dysfunction, and Hypoglycemia in Guideline-Directed Medical Therapy for Heart Failure: When to Tolerate and When to Worry. Rev Cardiovasc Med. 2026;27(2):45741. https:\/\/doi.org\/10.31083\/rcm45741.","journal-title":"Rev Cardiovasc Med"},{"issue":"2","key":"7904_CR37","doi-asserted-by":"publisher","first-page":"EVIDoa2300286","DOI":"10.1056\/EVIDoa2300286","volume":"3","author":"S James","year":"2024","unstructured":"James S, Erlinge D, Storey RF, et al. Dapagliflozin in Myocardial Infarction without Diabetes or Heart Failure. NEJM Evid. 2024;3(2):EVIDoa2300286. https:\/\/doi.org\/10.1056\/EVIDoa2300286.","journal-title":"NEJM Evid"},{"issue":"6","key":"7904_CR38","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1002\/ehf2.15420","volume":"12","author":"D Erlinge","year":"2025","unstructured":"Erlinge D, James S, Deanfield J, et al. Cardiometabolic outcomes with dapagliflozin after myocardial infarction by baseline ejection fraction: DAPA-MI. ESC Heart Fail. 2025;12(6):4184\u201393. https:\/\/doi.org\/10.1002\/ehf2.15420.","journal-title":"ESC Heart Fail"},{"issue":"1","key":"7904_CR39","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1186\/s12872-025-04992-2","volume":"25","author":"D Semirani-Nezhad","year":"2025","unstructured":"Semirani-Nezhad D, Soleimani H, Taebi M, et al. Early initiation of SGLT2 inhibitors in acute myocardial infarction and cardiovascular outcomes, an updated systematic review and meta-analysis. BMC Cardiovasc Disord. 2025;25(1):527. https:\/\/doi.org\/10.1186\/s12872-025-04992-2.","journal-title":"BMC Cardiovasc Disord"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-026-07904-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-026-07904-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-026-07904-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T12:31:25Z","timestamp":1782909085000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-026-07904-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":39,"alternative-id":["7904"],"URL":"https:\/\/doi.org\/10.1007\/s10557-026-07904-4","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"assertion":[{"value":"19 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was conducted in compliance with the ethical standards of the Declaration of Helsinki. The study protocol was approved by the Ethics Committee of Affiliated Hospital of Hebei University (Approval No. HDFFLL-IIT-2025-123).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"Patient consent to participate was waived by the Ethics Committee of Affiliated Hospital of Hebei University due to the retrospective and anonymized nature of the data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}